Valeant Pharmaceuticals International, Inc.
) recently announced that it has completed the previously
announced acquisition of Bausch + Lomb Holdings Incorporated.
We remind investors that the acquisition was announced in May
2013. Valeant paid $8.7 billion in cash for the acquisition.
With a history of 160 years, Bausch + Lomb currently has
recognized prescription and over the counter (OTC) brands such as
Besivance, Lotemax, Ocuvite and PreserVision and vision care
brands such as Biotrue ONEday, PureVision, renu and Boston.
The company also has surgical brands such as enVista, Storz,
Stellaris and VICTUS under its extensive portfolio.
The acquisition is expected to generate annual cost savings of
at least $800 million by the end of 2014, of which $500 million
is expected in 2013.
The acquisition will strengthen Valeant's ophthalmology
portfolio. Bausch + Lomb's three business units will be merged
into a new unit, Bausch + Lomb Eye Health.
We are encouraged by the company's integration efforts.
Valeant will reduce its headcount by 10% - 15%, primarily in
the U.S. and Canada. Moreover, Valeant is planning to
consolidate locations to streamline operations while improving
efficiencies. As per this plan, Valeant will move its newly
formed business unit, Bausch + Lomb Eye Health, to N.J. along
with its Medicis business.
We note that Valeant has been quite active on the acquisition
front. In Apr 2013, Valeant acquired Obagi Medical Products for
$440 million following a bidding war with Merz Pharma Group.
In Feb 2013, Valeant acquired Natur Produkt International for
$137 million. In Dec 2012, Valeant acquired the entire
outstanding common stock of Medicis Pharmaceutical Corporation
for approximately $2.6 billion.
We look forward to further updates on integration plans from
Valeant when it announces its second quarter results.
Valeant currently carries a Zacks Rank #3 (Hold). Right now,
) look attractive with a Zacks Rank #2 (Buy).
IRONWOOD PHARMA (IRWD): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SHIRE PLC-ADR (SHPG): Free Stock Analysis
VALEANT PHARMA (VRX): Free Stock Analysis
To read this article on Zacks.com click here.